Payment overview · 2025
General Payments
$1,269.49
58 reported records · 17 companies
Healthcare provider profile · identity verified
Jose Luis Prieto, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · WINTER HAVEN, FL · NPI 1144509480
Verified facts
What the public records show
CMS Open Payments records show Jose Luis Prieto, D.O. received $1,269.49 in general payments during 2025 across 58 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 345 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.14 | 15.0% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $148.52 | 11.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $119.30 | 9.4% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $102.16 | 8.1% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $100.84 | 7.9% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.73 | 7.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $95.49 | 7.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.69 | 5.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $66.96 | 5.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.59 | 4.8% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $52.59 | 4.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.47 | 3.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.95 | 3.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.81 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.31 | 1.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.00 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.94 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,269.49 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.20 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $122.15 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $119.30 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $103.48 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $102.16 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $95.49 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $95.11 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $76.82 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.68 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $66.96 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.59 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.26 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $52.59 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.45 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.45 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.52 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 345 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 219 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 121 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 28 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
36 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
219 | 64 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
28 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
219 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
65 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
345 | 86 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1271 | 369 |
| Amlodipine Besylate | Amlodipine Besylate | 846 | 270 |
| Levothyroxine Sodium | Levothyroxine Sodium | 614 | 181 |
| Lisinopril | Lisinopril | 604 | 173 |
| Losartan Potassium | Losartan Potassium | 536 | 169 |
| Pantoprazole Sodium | Pantoprazole Sodium | 466 | 155 |
| Gabapentin | Gabapentin | 426 | 135 |
| Furosemide | Furosemide | 409 | 125 |
| Metoprolol Tartrate | Metoprolol Tartrate | 398 | 99 |
| Omeprazole | Omeprazole | 361 | 108 |
| Metformin Hcl | Metformin Hcl | 358 | 112 |
| Trazodone Hcl | Trazodone Hcl | 350 | 101 |
| Eliquis | Apixaban | 345 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 334 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 331 | 110 |
| Alprazolam | Alprazolam | 325 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 317 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 101 |
| Famotidine | Famotidine | 284 | 90 |
| Simvastatin | Simvastatin | 280 | 88 |
| Tizanidine Hcl | Tizanidine Hcl | 280 | 94 |
| Potassium Chloride | Potassium Chloride | 256 | 71 |
| Tramadol Hcl | Tramadol Hcl | 243 | 77 |
| Sertraline Hcl | Sertraline Hcl | 239 | 64 |
| Montelukast Sodium | Montelukast Sodium | 238 | 71 |
| Pioglitazone Hcl | Pioglitazone Hcl | 221 | 71 |
| Jardiance | Empagliflozin | 219 | 64 |
| Finasteride | Finasteride | 215 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 205 | 59 |
| Allopurinol | Allopurinol | 197 | 62 |
| Azelastine Hcl | Azelastine Hcl | 188 | 95 |
| Glipizide | Glipizide | 171 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 77 |
| Celecoxib | Celecoxib | 161 | 56 |
| Azithromycin | Azithromycin | 160 | 113 |
| Carvedilol | Carvedilol | 150 | 53 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 147 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 145 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 47 |
| Clonidine Hcl | Clonidine Hcl | 140 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 32 |
| Alendronate Sodium | Alendronate Sodium | 135 | 38 |
| Pregabalin | Pregabalin | 135 | 35 |
| Methylprednisolone | Methylprednisolone | 134 | 121 |
| Hydralazine Hcl | Hydralazine Hcl | 133 | 36 |
| Donepezil Hcl | Donepezil Hcl | 127 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 32 |
| Lorazepam | Lorazepam | 123 | 34 |
| Ozempic | Semaglutide | 121 | 30 |
| Ezetimibe | Ezetimibe | 119 | 40 |
| Meloxicam | Meloxicam | 112 | 31 |
| Xarelto | Rivaroxaban | 109 | 25 |
| Prednisone | Prednisone | 108 | 48 |
| Myrbetriq | Mirabegron | 100 | 22 |
| Nystatin | Nystatin | 98 | 52 |
| Mirtazapine | Mirtazapine | 97 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 30 |
| Oxybutynin Chloride | Oxybutynin Chloride | 93 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 24 |
| Spironolactone | Spironolactone | 85 | 26 |
| Atenolol | Atenolol | 83 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 24 |
| Chlorthalidone | Chlorthalidone | 79 | 28 |
| Sildenafil Citrate | Sildenafil Citrate | 78 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 78 | 49 |
| Memantine Hcl | Memantine Hcl | 76 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 23 |
| Lactulose | Lactulose | 73 | 35 |
| Baclofen | Baclofen | 71 | 24 |
| Entresto | Sacubitril/Valsartan | 65 | 21 |
| Synthroid | Levothyroxine Sodium | 62 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 24 |
| Metformin Hcl Er | Metformin Hcl | 60 | 17 |
| Glimepiride | Glimepiride | 59 | 16 |
| Meclizine Hcl | Meclizine Hcl | 59 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 17 |
| Ibuprofen | Ibuprofen | 56 | 17 |
| Irbesartan | Irbesartan | 54 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | 11 |
| Diazepam | Diazepam | 53 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 41 |
| Valsartan | Valsartan | 52 | 13 |
| Divalproex Sodium | Divalproex Sodium | 50 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 21 |
| Bupropion Xl | Bupropion Hcl | 47 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 42 |
| Fenofibrate | Fenofibrate | 47 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 15 |
| Temazepam | Temazepam | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 15 |
| Bumetanide | Bumetanide | 43 | 13 |
| Estradiol | Estradiol | 43 | 13 |
| Lovastatin | Lovastatin | 43 | 11 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 42 | 13 |
| Farxiga | Dapagliflozin Propanediol | 42 | 17 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 41 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Mupirocin | Mupirocin | 39 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 12 |
| Fluconazole | Fluconazole | 37 | 28 |
| Buspirone Hcl | Buspirone Hcl | 36 | 12 |
| Prolia | Denosumab | 36 | 24 |
| Diltiazem Hcl | Diltiazem Hcl | 35 | suppressed |
| Glipizide Er | Glipizide | 35 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 11 |
| Nitroglycerin | Nitroglycerin | 34 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 12 |
| Ramipril | Ramipril | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 11 |
| Sucralfate | Sucralfate | 32 | 14 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 22 |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 24 |
| Ciclopirox | Ciclopirox | 27 | 17 |
| Linzess | Linaclotide | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Jantoven | Warfarin Sodium | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 17 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 12 |
| Topiramate | Topiramate | 18 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 16 |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Methazolamide | Methazolamide | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 13 | 11 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,269.49 · 58 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE, GEMTESA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error